Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 6, 2010, Pages 1026-1032

  Xu, Mingqing ^a,b,c,d,e   Xing, Qinghe ^b,f   Li, Sheng ^a,b   Zheng, Yonglan ^a,b   Wu, Shengnan ^a,b   Gao, Rui ^a,b   Yu, Lan ^a,b   Guo, Tingwei ^a,b   Yang, Yifeng ^a,b   Liu, Jixia ^a,b   Zhang, Aiping ^a,b   Zhao, Xinzhi ^b,f   He, Guang ^a,b   Zhou, Jian ^a,b   Wang, Lei ^a,b   Xuan, Jiekun ^a,b   Du, Jing ^a,b   Li, Xingwang ^a,b   Feng, Guoyin ^g   Lin, Zhiguang ^g   Xu, Yifeng ^d   St Clair, David ^h   Lin, Zhicheng ^e   He, Lin ^a,b,f   more..

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f FUDAN UNIVERSITY   (China)

^g SHANGHAI MENTAL HEALTH CENTER   (China)

^h UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Antipsychotics; Association study; Chlorpromazine; Clozapine; Dopamine transporter; Extrapyramidal syndrome; Genetic polymorphism; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE TRANSPORTER; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE TARGETING; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PHARMACOGENETICS; PROMOTER REGION; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT RESPONSE; CHEMICALLY INDUCED; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHLORPROMAZINE; CLOZAPINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77955057308     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.05.017     Document Type: Article

References (57)

1. Al Hadithy A.F., Wilffert B., Stewart R.E., Looman N.M., Bruggeman R., Brouwers J.R., et al. Pharmacogenetics of Parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:890-897.
2. Al Hadithy A.F., Ivanova S.A., Pechlivanoglou P., Wilffert B., Semke A., Fedorenko O., et al. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol 2010, 25:84-91.
3. Arranz M.J., Munro J., Birkett J., Bolonna A., Mancama D., Sodhi M., et al. Pharmacogenetic prediction of clozapine response. Lancet 2000, 355:1615-1616.
4. Ase A.R., Amdiss F., Hébert C., Huang N., van Gelder N.M., Reader T.A. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors. J Neural Transm 1999, 106:75-105.
5. Bamne M.N., Talkowski M.E., Chowdari K.V., Nimgaonkar V.L. Functional Analysis of Upstream Common Polymorphisms of the Dopamine Transporter Gene. Schizophr Bull Mar 9 2009, (in press).
6. Bannon M.J., Michelhaugh S.K., Wang J., Sacchetti P. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 2001, 11:449-455.
7. Brookes K.J., Mill J., Guindalini C., Curran S., Xu X., Knight J., et al. A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. Arch Gen Psychiatry 2006, 63:74-81.
8. Buckley P.F. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007, 68:5-9.
9. Carpenter W.T., Koenig J.I. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008, 33:2061-2079.
10. Drgon T., Lin Z., Wang G.J., Fowler J., Pablo J., Mash D.C., et al. Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol 2006, 26:875-889.
11. Erdfelder E., Faul F., Buchner A. G*Power: a general power analysis program. Behav Res Methods Instrum Comput 1996, 28:1-11.
12. Franke B., Hoogman M., Arias Vasquez A., Heister J.G., Savelkoul P.J., Naber M., et al. Association of the dopamine transporter (SLC6A3/DAT1) gene 9-6 haplotype with adult ADHD. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1576-1579.
13. Gamma F., Faraone S.V., Glatt S.J., Yeh Y.C., Tsuang M.T. Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene. Schizophr Res 2005, 73:55-58.
14. Genro J.P., Polanczyk G.V., Zeni C., Oliveira A.S., Roman T., Rohde L.A., et al. A common haplotype at the dopamine transporter gene 5' region is associated with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1568-1575.
15. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006, 29:303-319.
16. Gerlach J., Lublin H., Peacock L. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology 1996, 14:35S-39S.
17. Gomez A., Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 2009, 85:426-430.
18. Greenwood T.A., Kelsoe J.R. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 2003, 82:511-520.
19. Grünhage F., Schulze T.G., Müller D.J., Lanczik M., Franzek E., Albus M., et al. Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). Mol Psychiatry 2000, 5:275-282.
20. Guindalini C., Howard M., Haddley K., Laranjeira R., Collier D., Ammar N., et al. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci USA 2006, 103:4552-4557.
21. Güzey C., Scordo M.G., Spina E., Landsem V.M., Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 2007, 63:233-241.
22. Haddley K., Vasiliou A.S., Ali F.R., Paredes U.M., Bubb V.J., Quinn J.P. Molecular genetics of monoamine transporters: relevance to brain disorders. Neurochem Res 2008, 33:652-667.
23. Heinz A., Goldman D., Jones D.W., Palmour R., Hommer D., Gorey J.G., et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000, 22:133-139.
24. Janno S., Holi M.M., Tuisku K., Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol 2005, 5:5.
25. Kaiser R., Tremblay P.B., Klufmoller F., Roots I., Brockmoller J. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002, 7:695-705.
26. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
27. Keikhaee M.R., Fadai F., Sargolzaee M.R., Javanbakht A., Najmabadi H., Ohadi M. Association analysis of the dopamine transporter (DAT1)-67A/T polymorphism in bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2005, 35B:47-49.
28. Kelada S.N., Costa-Mallen P., Checkoway H., Carlson C.S., Weller T.S., Swanson P.D., et al. Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease. Pharmacogenet Genomics 2005, 15:659-668.
29. Khodayari N., Garshasbi M., Fadai F., Rahimi A., Hafizi L., Ebrahimi A., et al. Association of the dopamine transporter gene (DAT1) core promoter polymorphism -67T variant with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004, 129B:10-12.
30. Kim J.Y., Jung I.K., Han C., Cho S.H., Kim L., Kim S.H., et al. Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry Clin Neurosci 2005, 59:183-188.
31. Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004, 9:442-473.
32. Kirchheiner J., Gründemann D., Schömig E. Contribution of allelic variations in transporters to the phenotype of drug response. J Psychopharmacol 2006, 20:27-32.
33. Krebs M.O., Guillin O., Bourdell M.C., Schwartz J.C., Olie J.P., Poirier M.F., et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 2000, 5:558-562.
34. Lafuente A., Bernardo M., Mas S., Crescenti A., Aparici M., Gassó P., et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res 2007, 90:115-122.
35. Laucht M., Skowronek M.H., Becker K., Schmidt M.H., Esser G., Schulze T.G., et al. Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample. Arch Gen Psychiatry 2007, 64:585-590.
36. Leucht S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2004, 7:S15-S20.
37. Martinez D., Gelernter J., Abi-Dargham A., van Dyck C.H., Kegeles L., Innis R.B., et al. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001, 24:553-560.
38. Mehler-Wex C., Riederer P., Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 2006, 10:167-179.
39. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008, 13:27-35.
40. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Rep 1962, 10:799-812.
41. Potkin S.G., Basile V.S., Jin Y., Masellis M., Badri F., Keator D., et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 2003, 8:109-113.
42. Segman R.H., Goltser T., Heresco-Levy U., Finkel B., Shalem R., Schlafman M., et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003, 3:277-283.
43. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989.
44. Szekeres G., Kéri S., Juhász A., Rimanóczy A., Szendi I., Czimmer C., et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004, 124B:1-5.
45. Talkowski M.E., Kirov G., Bamne M., Georgieva L., Torres G., Mansour H., et al. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet 2008, 17:747-758.
46. van Dyck C.H., Malison R.T., Jacobsen L.K., Seibyl J.P., Staley J.K., Laruelle M., et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 2005, 46:745-751.
47. von Coburg Y., Kottke T., Weizel L., Ligneau X., Stark H. Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett 2009, 19:538-542.
48. Waldman I.D., Robinson B.F., Feigon S.A. Linkage disequilibrium between the dopamine transporter gene (DAT1) and bipolar disorder: extending the transmission disequilibrium test (TDT) to examine genetic heterogeneity. Genet Epidemiol 1997, 14:699-704.
49. Wilffert B., Al Hadithy A.F., Sing V.J., Matroos G., Hoek H.W., van Os J., et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J Psychopharmacol 2009, 23:652-659.
50. Xing Q., Gao R., Li H., Feng G., Xu M., Duan S., et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006, 7:987-993.
51. Xing Q., Gao R., Li H., Feng G., Xu M., Duan S., et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006, 7:987-993.
52. Xu M.Q., St Clair D., Ott J., Feng G.Y., He L. Brain-derived neurotrophic factor gene C-270T and Val66Met functional polymorphisms and risk of schizophrenia: a moderate-scale population-based study and meta-analysis. Schizophr Res 2007, 91:6-13.
53. Xu M.Q., St Clair D., Feng G.Y., Lin Z.G., He G., Li X., et al. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet Genomics 2008, 18:449-457.
54. Yang B., Chan R.C., Jing J., Li T., Sham P., Chen R.Y. A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:541-550.
55. Zalsman G., Frisch A., Lev-Ran S., Martin A., Michaelovsky E., Bensason D., et al. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol 2003, 13:183-185.
56. Zhang A., Xing Q., Wang L., Du J., Yu L., Lin Z., et al. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics 2007, 8:1337-1345.
57. Zhao J.H. 2LD, Genecounting and HAP: computer programs for linkage disequilibrium analysis. Bioinformatics 2004, 20:1325-1326.